GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset

GMED cut its 2026 revenue guidance to $3.09B from a prior range of $3.18B-$3.22B, a reduction of roughly $90M to $130M at the range's endpoints. The company held its non-GAAP earnings guidance steady, so the miss is on the top line, not the bottom.

Management pointed to three drivers: delayed spine product launches, slower sales rep productivity, and a 25.7% drop in Nevro sales. Each is company-specific execution friction rather than a demand-side warning, though the source ties the revenue shortfall to all three.

The pivot is 2027. Globus Medical is targeting growth from new products, including SCRIPT, EIQ, and HFX Elite, backed by cost discipline. That discipline helps explain how non-GAAP earnings guidance survived a lower revenue base. Interpretation: the market is being asked to look past 2026 and underwrite a launch-driven rebound that has already slipped once, given the delayed spine launches.

The setup is a classic reset: lower near-term revenue expectations, preserved earnings, and a growth narrative pushed out a year. The credibility of that narrative rests on launch timing, which the company has just missed.